Sequential intravenous/oral XXXX as an empiric antimicrobial therapy: results of a Canadian multicenter study. The Canadian Collaborative Investigational Group.

@entity1 @entity5572 @entity295 @entity55 @entity1066 @entity2177 @entity2688 @entity281 @entity79 @entity2679 @entity1729 @entity2885 @entity2335
An open-label, nonrandomized, multicenter study was designed to evaluate the efficacy and safety of intravenous (i.v.) @entity2177 , followed by oral @entity2177 and/or some other antimicrobial, as presumptive (empiric) therapy in hospitalized @entity1 with clinical and bacteriologic evidence of @entity281 . Out of a total of 149 @entity1 recruited by 31 physician investigators, 148 were assessable for the determination of clinical efficacy and 102 @entity1 were assessable for bacteriologic efficacy. All 149 @entity1 were included in the evaluation of the safety of i.v. @entity2177 . The mean duration of IV @entity2177 therapy was 6 days, and 111 @entity1 were subsequently switched to oral treatment with @entity2177 and/or some other antimicrobial. A clinically favorable response was achieved using i.v. @entity2177 in 48 (75%) of 64 @entity1 with @entity55 ; 4 (80%) of 5 @entity1 with other @entity1729 ( @entity1729 ); 21 (88%) of 24 @entity1 with @entity2885 ; all 7 (100%) @entity1 with complicated @entity2335 ; 16 (94%) of 17 @entity1 with other complicated urinary tract @entity281 (UTI); all 8 (100%) @entity1 with @entity2688 ; both (100%) @entity1 with infected @entity1066 ; 4 (80%) of 5 @entity1 with other skin or skin structure @entity281 ; 5 (83%) of 6 @entity1 with @entity79 ; all 8 (100%) @entity1 with @entity295 ; the 1 (100%) @entity1 with acute @entity2679 ; and the 1 (100%) @entity1 with @entity5572 . Of the 88 @entity1 from these @entity281 categories who were switched to oral @entity2177 , only 2 @entity1 (2.3%) were classified as a clinical failure at the end of all therapy. Eradication of the causative pathogen was demonstrated with i.v. @entity2177 in 18 (55%) of 33 assessable @entity1 with @entity55 ; 1 (25%) of 4 @entity1 with other @entity1729 ; 17 (81%) of 21 @entity1 with @entity2885 ; 3 (43%) of 7 @entity1 with complicated @entity2335 ; 9 (69%) of 13 @entity1 with other complicated UTI; 3 (60%) of 5 @entity1 with @entity2688 ; neither (0%) of the 2 @entity1 with infected @entity1066 ; 3 (50%) of 6 @entity1 with other skin or skin structure @entity281 ; 2 (33%) of 6 @entity1 with @entity79 ; and 4 (80%) of 5 @entity1 with @entity295 . A causative pathogen was not isolated in the 1 @entity1 with @entity5572 ; initial bacteriologic culture was not available for the @entity1 with acute @entity2679 . Of the 56 bacteriologically assessable @entity1 from these @entity281 categories who were switched to oral @entity2177 , there were only 3 @entity1 (5.4%) in whom the causative bacterial pathogens were not successfully eradicated at the end of all therapy. There were no unexpected adverse events with the use of i.v. @entity2177 .(ABSTRACT TRUNCATED AT 400 WORDS)
